---
title: "Rolling NDA Submissions Reshape Biotech Development Playbook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300554420.md"
description: "FDA's rolling NDA framework accelerates biotech development. UroGen advances bladder cancer therapy submissions, BioLife sees preservation tool demand rise, Heron streamlines pain management pathways, and BioXcel integrates AI to compress trials, signaling sector-wide operational refinement."
datetime: "2026-09-30T10:13:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300554420.md)
  - [en](https://longbridge.com/en/news/300554420.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300554420.md)
generator: "portal-rs"
---

# Rolling NDA Submissions Reshape Biotech Development Playbook

The FDA's rolling submission framework is redefining biotech development timelines. UroGen Pharma（URGN.US）leveraged the pathway for UGN-102, driving a 42% sequential revenue jump in Q2 2026 as it advances its bladder cancer therapy. BioLife Solutions（BLFS.US）saw preservation tool demand rise in tandem, with quarterly sales up 3.5%. Heron Therapeutics（HRTX.US）streamlined HTX-011's regulatory path for post-surgical pain, while BioXcel Therapeutics（BIXI.US）integrated AI to compress trial phases. Minerva Neurosciences（STIM.US）and BioTelemetry（BIOT.US）are testing the model in neurology and remote diagnostics, signaling a sector-wide shift toward modular development.

### Related Stocks

- [BIOT.US](https://longbridge.com/en/quote/BIOT.US.md)
- [BLFS.US](https://longbridge.com/en/quote/BLFS.US.md)
- [BIXI.US](https://longbridge.com/en/quote/BIXI.US.md)
- [HRTX.US](https://longbridge.com/en/quote/HRTX.US.md)
- [STIM.US](https://longbridge.com/en/quote/STIM.US.md)
- [URGN.US](https://longbridge.com/en/quote/URGN.US.md)

## Related News & Research

- [Neuronetics, Inc. (NASDAQ:STIM) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages](https://longbridge.com/en/news/301021406.md)
- [Heron Therapeutics Expands U.S. Portfolio Through Licensing Deal](https://longbridge.com/en/news/300486499.md)
- [BioLife Solutions holds special shareholder meeting on merger agreement vote](https://longbridge.com/en/news/301040405.md)
- [Instinct Bio named CelSiege representative for IN01 cancer immunotherapy in Japan, China](https://longbridge.com/en/news/300668549.md)
- [Heron Therapeutics signs US multi-product development, license deal with Long Grove Pharmaceuticals](https://longbridge.com/en/news/300483682.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**